

1 Article

# 2 Gut microbiome and lichen sclerosis: a two-sample 3 bi-directional Mendelian randomization study

4 Jiayan Chen<sup>1,†</sup>, Peiyan Wang<sup>2,†</sup>, Changji Xiao<sup>3</sup>, Kalibinuer Kelaimu<sup>3</sup>, Xianshu Gao<sup>1</sup>, Xiaomei Li<sup>1</sup>, Jun  
5 Hu<sup>3\*</sup>

6 <sup>1</sup> Department of Radiation Oncology, Peking University First Hospital, Beijing, China; chenjiayan2019-ro@bjmu.edu.cn (J.-Y.C.);  
7 doctorgaoxs@126.com (X.-S.G.); [lixiaomei1973@bjmu.edu.cn](mailto:lixiaomei1973@bjmu.edu.cn) (X.-M.L.);

8 <sup>2</sup> School of Information, University of Michigan, Ann Arbor, MI, United States; peiyanw@umich.edu (P.-Y.W.);

9 <sup>3</sup> Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing, China; xcji1988@163.com (C.-J.X.);  
10 13400052009@163.com (K.K.)

11 \* Correspondence: [hujunpkufh@bjmu.edu.cn](mailto:hujunpkufh@bjmu.edu.cn) (J.H.)

12 † These authors contributed equally to this work.

13 **Abstract:** (1) Background: Recent studies suggest a potential link between gut microbiomes (GMs) and inflammatory diseases, but  
14 the role of GMs in lichen sclerosis (LS) remains unclear. This study aims to investigate the causal relationship between GMs and LS,  
15 focusing on key GM taxa. (2) Methods: We utilized GWAS summary statistics for 211 GM taxa and their association with 2,445 LS  
16 patients and 353,088 healthy controls, employing Mendelian randomization (MR). GWAS data for GM taxa came from the  
17 MiBioGen consortium, and for LS from the FinnGen consortium. The primary analytical tools included the inverse-variance  
18 weighted (IVW) method, weighted MR, simple mode, weighted median, and MR-Egger methods. Sensitivity analyses included  
19 leave-one-out analysis, MR-Egger intercept test, MR-PRESSO global test, and Cochran's Q-test. A reverse MR analysis was  
20 conducted on bacteria identified in the forward MR study. (3) Results: We identified one strong causal relationship: order  
21 *Burkholderiales* [odds ratio (OR) = 0.420, 95% confidence interval (CI): 0.230 - 0.765, p = 0.005], and three nominally significant  
22 relationships: phylum *Cyanobacteria* (OR = 0.585, 95% CI: 0.373 - 0.919, p = 0.020), class *Betaproteobacteria* (OR = 0.403, 95%  
23 CI: 0.189 - 0.857, p = 0.018), and genus *Butyrivibrio* (OR = 0.678, 95% CI: 0.507 - 0.907, p = 0.009). Moreover, this MR analysis  
24 was not impacted by horizontal pleiotropy, according to the MR-Egger intercept test and MR-PRESSO global test (p > 0.05).  
25 Remarkably, the reliability of our results was confirmed by leave-one-out analysis. Reverse MR analysis showed no significant  
26 causal relationship between LS and GM. (4) Conclusions: This MR study identifies specific gut flora linked to a lower risk of LS,  
27 offering new insights for disease treatment and prevention. Future research should incorporate metagenomics sequencing of  
28 extensive microbiome GWAS datasets.

29 **Keywords:** gut microbiome, lichen sclerosis, causal relationship, Mendelian randomization, genome-wide association study  
30

## 31 1. Introduction

32 Lichen sclerosis (LS) is a chronic mucocutaneous immune-mediated disease that is characterized by skin atrophy  
33 and hypopigmentation [1]. A majority of the LS patients, exceeding 80%, present with anogenital lesions. Common  
34 Typical extragenital sites involve neck, shoulders, upper trunk, and thighs [2]. The typical clinical presentation  
35 consists of persistent white atrophic patches in the external genitalia, often accompanied by discomfort and itching.  
36 Potentially, the lesions could worsen and cause the vaginal introitus to constrict and scar, which would impair  
37 urogenital and sexual function. Furthermore, women with vulvar LS have a high risk of squamous cell carcinoma with  
38 a lifetime incidence rate ranging from 0.4% to 6% [3-4]. The prevalence of genital LS was reported to be 1.7% in  
39 gynecological practice [5]. However, the precise incidence of LS remains understated. LS can manifest at any age and  
40 has an impact on both sexes, with a prevalence ratio of females to males ranging from 3:1 to 10:1 [6]. Postmenopausal  
41 women are most commonly affected, followed by men, prepubertal children, and adolescents [7].


42 It is still difficult to fully comprehend the pathophysiology of LS. LS is characterized by a hereditary and familial  
43 propensity; however, chronic irritation, endocrine status, and autoimmune diseases may also contribute to the  
44 pathogenesis [8-11]. The microbiota is a key immune system modulator that contributes significantly to homeostasis  
45 maintenance. Over the past 20 years, numerous investigations have been carried out to examine the constitution and  
46 the inflammatory function of intestinal bacterial flora in preclinical and clinical studies focusing on dermatologic  
47 conditions, such as alopecia areata, rosacea, atopic dermatitis, and psoriasis [12-14]. Certain notable associations  
48 between microbiome signatures have been discovered. The relationship between LS and gut microbiota, however, is  
49 poorly understood. This study, therefore, has not been certified by peer review and should not be used to guide clinical practice.  
50

51 In epidemiological research, the Mendelian randomization (MR) method, which employs genetic variants as an  
52 instrumental variable, is widely used to investigate, the potential causal effect of exposure to specific diseases. In the  
53 MR approach, the genetic alleles could be randomly distributed like a randomized controlled trial, which is less likely  
54 to be impacted by confounding or reverse causation. Hence, we conducted a bidirectional large-scale MR analysis to  
55 identify potentially influential GM taxa using summary data from GWAS in order to shed light on the prevention and  
56 treatment of LS.

## 57 2. Materials and Methods

### 58 2.1. Study design

59 Figure 1 shows the design of the two-sample MR analysis. We followed three important MR assumptions to  
60 determine the possible causal association between GM and LS risk: IVs must be correlated with GM, they must be  
61 independent of confounding variables, and IVs must only affect LS risk through GM [15].



62  
63 **Figure 1.** Study design and workflow.

### 64 2.2. Exposure data

65 16S fecal microbiome rRNA gene sequencing profiles and host genotypes of 18,340 participants were examined  
66 in-depth by the MiBioGen consortium [16]. A comprehensive GWAS encompassing 211 GM taxa from genus to phylum  
67 revealed genetic variations linked to 9 phyla, 16 classes, 20 orders, 35 families, and 131 genera. The GM GWAS  
68 summary statistics can be accessed by downloading them from <https://mibiogen.gcc.rug.nl/> [17–19].

### 69 2.3. Outcome data

70 We acquired LS-related GWAS summary statistics from the FinnGen consortium R9 release, encompassing 2,445  
71 cases and 353,088 controls, available at <https://r9.finnngen.fi/>. It is noteworthy that our study, relying on publicly  
72 available databases, did not require additional ethics approval or informed consent.

### 73 2.4. Instrumental variable (IV) selection

74 In this MR study, single-nucleotide polymorphism (SNP) that exhibited strong association with each GM taxon  
 75 were utilized as IVs. For a more comprehensive analysis, IVs achieving locus-wide significance ( $p < 1 \times 10^{-6}$ ) were  
 76 selectively employed. Concurrently, the PLINK clumping method was applied to exclude SNPs in linkage  
 77 disequilibrium ( $r^2 < 0.001$ ,  $kb = 10,000$ ). The degree of weak instrumental bias was then estimated using the  
 78 F-statistic of IVs, where a value of  $>10$  indicated the lack of bias resulting from weak IVs [20]. Palindromic SNPs and  
 79 those not found in the outcome were finally eliminated from the instrumental variable group.

## 80 2.5. Statistical analysis

81 The IVW approach, an extension of the Wald ratio estimator based on meta-analysis principles, was the main  
 82 technique used in this MR investigation to infer causality [21]. Four more MR methods—MR-Egger, weighted median,  
 83 weighted mode, and simple mode—were then utilized to supplement the IVW results if the IVW technique showed a  
 84 causal association ( $p < 0.05$ ) for each GM taxon [22–23]. At the p-value of less than 0.05, causal relationships were  
 85 shown as OR with 95% CI. False discovery rate (FDR) correction was used with a threshold of  $q < 0.05$  to address  
 86 multiple tests. Exposure-outcome couples exhibiting a consistent direction were required to demonstrate consistency  
 87 across all MR techniques, demonstrating a causal link. Many sensitivity studies were carried out in order to evaluate  
 88 the stability of causal associations. The horizontal pleiotropy was determined using the MR-Egger intercept test and  
 89 the MR-PRESSO global test [24–25]. Moreover, result robustness was evaluated using a leave-one-out analysis.  
 90 Reverse MR studies were conducted to examine if identified major bacterial genera were causally impacted by LS,  
 91 employing SNPs linked with LS as IVs. The R software's "TwoSampleMR" and "MR-PRESSO" packages (version 4.2.2)  
 92 served as the foundation for all studies.

## 93 3. Results


### 94 3.1. IVs Overview

95 At the phylum, class, order, family, and genus levels, we found a total of 16, 26, 26, 54, and 149 SNPs linked to  
 96 GM, with a significance level of  $p < 1 \times 10^{-6}$ . Notably, every IV showed stronger correlations between exposure and  
 97 result ( $P_{\text{exposure}} < P_{\text{outcome}}$ ), and every F-value was greater than 10. Supplementary Table S1 has comprehensive  
 98 information about the IVs.


### 99 3.2. MR Analysis

100 In our implementation of the Inverse Variance Weighted Fixed Effects (IVW-FE) technique to assess the causal  
 101 relationship between LS and 211 GM taxa in five hierarchical levels, several taxa were identified as potentially  
 102 influencing LS risk. Specifically, phylum *Cyanobacteria* (id: 1500), class *Betaproteobacteria* (id: 2867), order  
 103 *Burkholderiales* (id: 2874), and genus *Butyrivibrio* (id: 1993) exhibited a decreased risk for LS (Figure 2). Following  
 104 FDR correction, the protective effect of order *Burkholderiales* (id: 2874) [OR= 0.420 (0.230 - 0.765),  $p = 0.005$ ,  $q =$   
 105  $0.036$ ] against LS remained significant. Importantly, Cochran's Q test results indicated an absence of heterogeneity.

106 To further support the causal relationship between these GM taxa and LS, we utilized four more MR techniques:  
 107 MR-Egger, weighted median, weighted mode, and simple mode (Figure 3). The robustness of our observed causal  
 108 relationships was reinforced by the encouraging consistency of the results obtained from these approaches with the  
 109 IVW findings.



110  
 111 **Figure 2.** MR results of causal effects between GM and LS risk.  
 112



113  
114 **Figure 3.** Various MR outcomes for four GM taxa with identified causal associations to LS.

115 **3.3. Sensitivity analysis**

116 The MR-Egger intercept test results revealed no horizontal pleiotropy ( $p > 0.05$ ) within the IVs associated with  
117 order *Burkholderiales* (id: 2874) and LS (Supplementary Table S2). Furthermore, the leave-one-out analysis  
118 demonstrated the robustness of the MR results, as the removal of any particular IV did not change the overall findings  
119 for order *Burkholderiales* (id: 2874) (Supplementary Figure S1). It is noteworthy, however, that due to an insufficient  
120 number of SNPs, MR-Egger intercept tests and leave-one-out analyses could not be conducted for the remaining three  
121 gut microbiota taxa. Similarly, the MR-PRESSO global test was precluded for the same reason.

122 **3.4. Reverse MR**

123 Nine SNPs linked to LS were found to be eligible IVs after a thorough series of IV screening procedures  
124 (Supplementary Table S3). The findings of the reverse MR analysis, displayed in Supplementary Table S4, yielded  
125 no proof of a causal effect from LS to the determined bacterial taxa. The results of the MR-Egger intercept test and the  
126 MR-PRESSO global test both indicated that there was no horizontal pleiotropy among the remaining IVs. A  
127 comprehensive presentation of the sensitivity tests can be found in Supplementary Table S5, demonstrating the  
128 robustness of our findings in the face of various analytical challenges.

129 **4. Discussion**

130 The gut microbiota is one of the potential targets for regulating the host's immune responses. The correlation  
131 between the composition of the gut microbiome and the immunological system regulation has provided a novel  
132 perspective on the pathogenesis of numerous chronic multifactorial diseases. According to multiple studies that link  
133 gastrointestinal homeostasis to skin disorders, both the component and function of the GM are altered in patients with  
134 autoimmune and inflammatory skin diseases. Atopic dermatitis (AD) development and progression may be influenced  
135 by alterations in the microbiota diversity. For instance, decreased variation of the GM is associated with more severe  
136 disease. Recent evidence suggests that microbiota could be involved in modifying itchiness in atopic dermatitis  
137 through the interactions between the gut, skin and brain. Damage to the epidermal barrier, brain sensitization of  
138 pruritus-generating mechanisms, and modulation of histamine-independent itch are caused by the presence of  
139 proinflammatory cytokines, microbial metabolites, and a compromised immune response [26]. Microbiota dysbiosis  
140 was found to induce an irregular immune response in individuals with psoriasis, and the alterations of microbiota  
141 composition were linked to the level of inflammation-related biomarkers that were abnormal in the patients with  
142 psoriasis. For example, the relative abundances of *Phascolarctobacterium* and *Dialister* may serve as possible  
143 indicators of the psoriasis progression, as the IL-2 receptor showed a positive correlation with the former and a  
144 negative correlation with the latter [27].

145 However, only a few studies have shown a link between changes in GM and LS disease. Chattopadhyay et al.  
146 conducted a pilot case-control study with prepubescent females, which suggested that the females with vulvar LS  
147 exhibited an increased relative abundance of *Escherichia coli*, *Bifidobacterium adolescentis*, *Akkermansia muciniphila*,  
148 *Clostridiales* spp., *Paraprevotella* spp., and *Dialister* spp in comparison to healthy controls, while the abundance  
149 of *Roseburia faecis* and *Ruminococcus bromii* was noticeably decreased. These findings showed a potential correlation  
150 between intestinal dysbiosis and juvenile vulvar LS [28]. Nygaard et al.'s study revealed that women with LS had a  
151 higher relative abundance of phylum Euryarchaeota in their GM than controls [29]. However, the inconsistent  
152 findings and small sample of these studies pose challenges to reaching generalizable conclusions. Additionally, due to  
153 variations in gender, race, age, and body region, the composition of the GM may also differ among studies. The  
154 presence of these unclear factors impedes the ability to establish a causal relationship between GM and the risk of LS  
155 disease.

Our work thoroughly evaluated the causative influence of 211 GM taxa (from phylum to genus level) on LS, emphasizing the importance of GMs in LS. Four causal links in all were found, three of which were nominal and one of which was strong. Our MR analysis has provided the first confirmation that class *Betaproteobacteria* (id.2867), genus *Butyrivibrio* (id.1993), order *Burkholderiales* (id.2874), phylum *Cyanobacteria* (id.1500) have a protective effect LS. Most of these bacteria belong to Phylum Firmicutes and Proteobacteria, which was consistent with our previous research with vulvar skin microbiota [30]. It indicates an interesting linkage between gut and genital skin microbiota. As far as we know, this is the first MR investigation to look into the possibility of a causal relationship between gut microbiota and LS. In accordance with researches in other inflammatory diseases, our results suggest that gut dysbiosis may play a role in the development of LS.

It was believed that the metabolic activity and immunological response of gut microbiome may affect skin conditions [31]. The gut barrier integrity is primarily maintained by the microbial communities, through the conversion of polysaccharides and vitamins, as well as short-chain fatty acids. For example, butyrate reduces interstitial barrier permeability and improves the integrity of the epithelial barrier. Genus *Butyrivibrio*, class *Betaproteobacteria*, and order *Burkholderiales* are commensal bacteria that are well recognized for their capacity to generate short-chain fatty acids, particularly butyrate, which could help maintain systemic immunity balance [32]. Butyrate serves as the main source of energy for the colonic epithelium and exerts anti-inflammatory effects in the colonic mucosa by preventing the activation of NF- $\kappa$ B [33]. Several studies have shown that patients with Crohn's disease and ulcerative colitis, respectively, have a decreased enrichment of *Butyrivibrio* in colon and saliva samples than healthy controls, respectively [34-35]. Additionally, lower concentrations of stool butyrate have been observed in those suffering from inflammatory bowel disease (IBD), providing more evidence to support the possibility that gut dysbiosis plays a causal role in inflammatory conditions like IBD and potentially LS. Nevertheless, the relationship between skin disease and immunological activity triggered by the gut microbiome remains obscure, and further investigation is needed.

Our work contributed substantial evidence to the current literature concerning the causal relationship between gut microbiota and LS. The primary benefits of our research are: (1) We analyzed genetic data from a large sample group, which increases the reliability of the results in comparison to smaller observational research. (2) Through MR analysis, confounding variables are eliminated from causal association, and the causal association identified in our study may serve as potential candidates for future functional investigations. This study has some limitations that should be mentioned. The primary limitation of our work is that the most of participants in our research were limited to people who had European origins. Although reducing bias caused by population heterogeneity would be achieved, further research is necessary to explore whether the MR results can be general in other populations. Second, in order to obtain a greater number of SNPs, we relaxed the p threshold, which may heighten the likelihood of contravening the basic MR design premise. However, all SNPs have F statistic greater than 10, which indicates that all weak SNPs were excluded from the MR estimation. And rigorous FDR correction was applied to identify the significant results to reduce the likelihood of false-positive findings. Third, we were unable to fully reduce pleiotropy due to the fact that the specific biological functions of the utilized SNPs are still unknown. However, it is encouraging to note that distinct MR models generated consistent estimates, and the analyses of sensitivity analyses under various assumptions were unable to identify any horizontal pleiotropy. Studies have indicated that LS patients frequently exhibit several comorbidities, such as depression and behavioral disorders. The prevalence rates of these comorbidities may reach 37% and 63%, respectively [36-37]. Many of these comorbidities have been demonstrated to have an association with the GM [38]. Therefore, it is exceedingly probable that variations in GM exist between the patients with LS alone and those with LS accompanied by other medical conditions. However, the original GWAS data failed to make the distinction, thus additional research is required to solve this limitation.

## 5. Conclusions

Our study serves as a foundation for recognizing the causal association between the gut microbiota and LS. In addition, it was found that a number of gut flora may lower the incidence of LS. These findings hold promise for their prospective use in the prevention and management of LS. This would have an implication to clinicians that microbiome-targeted therapies might be promising preventive and therapeutic tools for LS. Future investigation is required to unravel the fundamental mechanism. Additional observational studies or lab-based research is warranted to substantiate these results.

**Supplementary Materials:** The following supporting information can be downloaded at: [www.mdpi.com/xxx/s1](http://www.mdpi.com/xxx/s1), Figure S1: title; Table S1: title; Video S1: title.

**Author Contributions:** Jiayan Chen, Peiyan Wang, and Jun Hu designed the research. Peiyan Wang collected and analyzed the data. Xianshu Gao and Xiaomei Li offered technical advice. Jiayan Chen, Peiyan Wang, and Jun Hu drafted the manuscript. Jun Hu supervised the study. Changji Xiao and Kalibinuer Kelaimu revised the manuscript. All authors approved the submitted version of the article and participated in its writing.

**Funding:** This research was funded by Peking University Youth Physician Research Funding (2015QN031) and National High Level Hospital Clinical Research Funding (Scientific Research Seed Fund of Peking University First Hospital 2023SF08).

**Data Availability Statement:** The summary data of MiBioGen can be downloaded from the website <https://mibiogen.gcc.rug.nl/>. The summary data of FINNGEN can be downloaded from the website <https://r9.finngen.fi/>. This published work and its supplementary information files contain other datasets that were generated and/or analyzed during the current study, which are accessible to the public.

218 **Acknowledgments:** The researchers of MiBioGen and FinnGen, as well as the members of all GWAS cohorts that were used in  
219 this study, are appreciated by the authors for providing the GWAS summary statistics.

220 **Conflicts of Interest:** The authors declare no conflicts of interest.

221

## References

- Papini, M, Russo, A, Simonetti, O, Borghi, A, Corazza, M, Piaserico, S, et al. Mucous membrane disorders research group of SIDeMaST. Diagnosis and management of cutaneous and anogenital lichen sclerosis: recommendations from the Italian Society of Dermatology (SIDeMaST). *Ital J Dermatol Venerol.* 2021,156:519–533.
- Kaufman, RH, DiPaola, GR, Friedrich, EG Jr, Hewitt, J, and Woodruff, JD. New nomenclature for vulvar disease. *J Cutan Pathol.* 1976,3:159–161.
- Chamli A, Souissi A. Lichen Sclerosus. Treasure Island (FL): StatPearls; 2022.
- Meani R, Howard A, Veysey E. Incidence of vulvar squamous cell carcinoma in women with vulval lichen sclerosis in an Australian tertiary referral centre. *The Australasian journal of dermatology.* 2019,60(1):76-77
- Bieber AK, Steuer AB, Melnick LE, Wong PW, Pomeranz MK, Autoimmune and Dermatologic Conditions Associated with Lichen Sclerosus, *Journal of the American Academy of Dermatology.* 2020, 85(1):228-229.
- Kirtschig, G, Becker, K, Günthert, A, Jasaitiene, D, Cooper, S, Chi, CC, et al. Evidence- based (S3) guideline on (anogenital) lichen sclerosis. *J Eur Acad Dermatol Venereol.* 2015, 29(10):e1-43.
- Krapf, JM, Mitchell, L, Holton, MA, and Goldstein, AT. Vulvar lichen Sclerosus: current perspectives. *Int J Women's Health.* 2020,12:11–20.
- Etiology, Clinical Features, and Diagnosis of Vulvar Lichen Sclerosus: A Scoping Review. *Obstet Gynecol Int.* 2020,2020:7480754
- Vulvar Lichen Sclerosus from Pathophysiology to Therapeutic Approaches: Evidence and Prospects. *Biomedicines.* 2021 ,9(8):950.
- Birenbaum DL, Young RC. High prevalence of thyroid disease in patients with lichen sclerosis, *J Reprod Med.* 2007,52:28-30
- The prevalence of self-reported medical comorbidities in patients with vulvar lichen sclerosis: A single-center retrospective study. *Int J Gynaecol Obstet.* 2021,153(2):340-343.
- Mahmud MR, Akter S, Tamanna SK, Mazumder L, Esti IZ, Banerjee S, Akter S, Hasan MR, Acharjee M, Hossain MS, Pirttilä AM. Impact of gut microbiome on skin health: gut-skin axis observed through the lenses of therapeutics and skin diseases. *Gut Microbes.* 2022 Jan-Dec;14(1):2096995.
- Moniaga CS, Tominaga M, Takamori K. An Altered Skin and Gut Microbiota Are Involved in the Modulation of Itch in Atopic Dermatitis. *Cells.* 2022 Dec 5;11(23):3930.
- Buhaş MC, Gavrilaş LI, Candrea R, Cătinean A, Mocan A, Miere D, Tătaru A. Gut Microbiota in Psoriasis. *Nutrients.* 2022 Jul 20;14(14):2970.
- Davies, N. M., Holmes, M. V., and Davey Smith, G. (2018). Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. *BMJ* 362:k601. doi: 10.1136/bmj.k601
- Kurilshikov A, Medina-Gomez C, Bacigalupe R, et al. Large-scale association analyses identify host factors influencing human gut microbiome composition. *Nat Genet.* 2021 Feb;53(2):156-165. doi: 10.1038/s41588-020-00763-1.
- Swertz MA, Jansen RC. Beyond standardization: dynamic software infrastructures for systems biology. *Nat Rev Genet.* 2007 Mar;8(3):235-43. doi: 10.1038/nrg2048.
- Swertz MA, Dijkstra M, Adamusiak T, et al. The MOLGENIS toolkit: rapid prototyping of biosoftware at the push of a button. *BMC Bioinformatics.* 2010 Dec 21;11 Suppl 12(Suppl 12):S12. doi: 10.1186/1471-2105-11-S12-S12.
- van der Velde KJ, Imhann F, Charbon B, et al. MOLGENIS research: advanced bioinformatics data software for non-bioinformaticians. *Bioinformatics.* 2019 Mar 15;35(6):1076-1078. doi: 10.1093/bioinformatics/bty742.
- Palmer, T. M., Lawlor, D. A., Harbord, R. M., Sheehan, N. A., Tobias, J. H., Timpson, N. J., et al. (2012). Using multiple genetic variants as instrumental variables for modifiable risk factors. *Stat. Methods Med. Res.* 21, 223–242. doi: 10.1177/0962280210394459
- Pagoni P, Dimou NL, Murphy N, Stergiakouli E. Using Mendelian randomisation to assess causality in observational studies. *Evid Based Ment Health.* 2019 May;22(2):67-71. doi: 10.1136/ebmental-2019-300085.
- Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genet Epidemiol.* 2016 May;40(4):304-14. doi: 10.1002/gepi.21965.
- Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. *Eur J Epidemiol.* 2017 May;32(5):377-389. doi: 10.1007/s10654-017-0255-x.
- Rees JMB, Wood AM, Burgess S. Extending the MR-Egger method for multivariable Mendelian randomization to correct for both measured and unmeasured pleiotropy. *Stat Med.* 2017 Dec 20;36(29):4705-4718. doi: 10.1002/sim.7492.
- Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat Genet.* 2018 May;50(5):693-698. doi: 10.1038/s41588-018-0099-7.
- Moniaga CS, Tominaga M, Takamori K. An Altered Skin and Gut Microbiota Are Involved in the Modulation of Itch in Atopic Dermatitis. *Cells.* 2022 Dec 5;11(23):3930
- Zhang, X.; Shi, L.; Sun, T.; Guo, K.; Geng, S. Dysbiosis of Gut Microbiota and Its Correlation with Dysregulation of Cytokines in Psoriasis Patients. *BMC Microbiol.* 2021, 21, 78.
- Chattopadhyay S, Arnold JD, Malayil L, Hittle L, Mongodin EF, Marathe KS, et al. (2021) Potential role of the skin and gut microbiota in premenarchal vulvar lichen sclerosis: A pilot case- control study. *PLoS ONE* 16(1): e0245243.
- Nygaard S, Gerlif K, Bundgaard-Nielsen C, Saleh Media J, Leutscher P, Sørensen S, Brusen Villadsen A, Thomsen Schmidt Arenholt L. The urinary, vaginal and gut microbiota in women with genital lichen sclerosis - A case-control study. *Eur J Obstet Gynecol Reprod Biol.* 2023 Oct;289:1-8.
- Liu X, Zhuo Y, Zhou Y, Hu J, Wen H and Xiao C (2022) Analysis of the Vulvar Skin Microbiota in Asymptomatic Women and Patients With Vulvar Lichen Sclerosus Based on 16S rRNA Sequencing. *Front. Cell Dev. Biol.* 10:842031.
- Salem I, Ramser A, Isham N, Ghannoum MA. The gut microbiome as a major regulator of the gut-skin axis. *Front Microbiol.* 2018;9:1459.
- Tamanai-Shacoori Z, Smida I, Bousarghin L, Loreal O, Meuric V, Fong SB, et al. Roseburia spp.: a marker of health? *Future Microbiol.* 2017; 12:157–70.
- Segain JP, Raingeard de la Blé tière D, Bourreille A, Leray V, Gervois N, Rosales C., et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. *Gut.* 2000; 47:397–403

- 293 34. Masoodi I, Alsharqeti AS, Ahmad S, Alyamani EJ, Al-Lehibi AA, Qutub AN, ALSyari KN, Alomair AO. Microbial dysbiosis in  
294 inflammatory bowel diseases: results of a metagenomic study in Saudi Arabia. *Minerva Gastroenterol Dietol.* 2019  
295 Sep;65(3):177-186.
- 296 35. Gryaznova MV, Solodskikh SA, Panevina AV, Syromyatnikov MY, Dvoretzkaya YD, Sviridova TN, Popov ES, Popov  
297 VN. *Heliyon.* Study of microbiome changes in patients with ulcerative colitis in the Central European part of Russia.  
298 *Heliyon.* 2021 Mar 10;7(3):e06432.
- 299 36. Bell SG, Kobernik EK, Haefner HK, Welch KC. Association Between Vulvar Squamous Intraepithelial Lesions and Psychiatric  
300 Illness. *J Low Genit Tract Dis.* 2021 1;25(1):53-56.
- 301 37. Malandrone F, Bevilacqua F, Merola M, Gallio N, Ostacoli L, Carletto S, Benedetto C. The Impact of Vulvar Cancer on  
302 Psychosocial and Sexual Functioning: A Literature Review. *Cancers (Basel).* 2021 Dec 23;14(1):63.
- 303 38. Socala, K., Doboszevska, U., Szopa, A., Serefko, A., Włodarczyk, M., Zielińska, A., et al. (2021). The role of  
304 microbiota-gut-brain axis in neuropsychiatric and neurological disorders. *Pharmacol. Res.* 172:105840.

305 **Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual  
306 author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury  
307 to people or property resulting from any ideas, methods, instructions or products referred to in the content.